Chronic kidney disease (stages four and five) and peripheral arterial disease are due to be added to the GP chronic disease management (CDM) treatment programme this year.
The CDM treatment programme is for patients who have a medical or GP visit card and a diagnosis of one or more of a number of specified chronic diseases.
The HSE confirmed that funding has been provided by the Department of Health to implement phase four of the CDM programme this year.
“Phase four will provide eligible people aged 18 years and over with access to the CDM treatment programme for… chronic kidney disease stages four or five [and] peripheral arterial disease,” a HSE spokesperson told the Medical Independent.
This year, the prevention component of the CDM programme is also due to be extended to “eligble people at risk of developing or who have” chronic kidney disease (stages one to three), valvular heart disease, and familial hypercholesterolaemia.
Currently, the prevention programme is for eligible adults at high risk of cardiovascular disease or diabetes, people diagnosed with hypertension, and all eligible women who had gestational diabetes or pre-eclampsia.
“The inclusion of these five conditions [to the treatment and prevention components] continues to support the ongoing implementation of Sláintecare,” according to the HSE.
“Consideration may be given to including patients with obesity and comorbidities in the programme in future years. This will be dependent on funding and anti-obesity medication availability.”
The third report of the CDM programme is due to be completed before the end of this month. This report will review data on patients registered in the first four years of the programme.
The CDM programme, which commenced in 2020, has been rolled out on a phased basis to adults with a medical or GP visit card. Over 90 per cent of eligible GPs have signed up to provide the programme.
Leave a Reply
You must be logged in to post a comment.